// App-Quantinova.ai

POS0536 (2021) : FILGOTINIB DEMONSTRATES CLINICAL EFFICACY IN RHEUMATOID ARTHRITIS INDEPENDENT OF SMOKING STATUS: A POST-HOC SUBGROUP ANALYSIS OF THREE PHASE 3 CLINICAL TRIALS

Researchers

Presenter

  • P. Emery

Principal Investigators

  • B. Downie

  • J. Liu

  • R. Hawtin

  • J. R. Curtis

  • G. R. Burmester

Medical Centers

  • University of Sheffield School of Medicine, Sheffield, United Kingdom

  • 1.Gilead Science Inc, Foster City, United States of America

  • University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL

  • Charite Universitatsmedizin der HU-Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany

Locations

  • United Kingdom

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02886728

  • NCT02889796

  • NCT02873936

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved